Related Experiment Video
Updated: Aug 11, 2026
06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
Genetic alterations in patients with primary aldosteronism
1Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan. takeday@im2.m.kanazawa-u.ac.jp
Summary
Genetic analysis of primary aldosteronism subtypes revealed no mutations in key genes. Overexpression of CYP11B2 mRNA in idiopathic hyperaldosteronism suggests other factors contribute to aldosterone overproduction.
Area of Science:
- Endocrinology
- Genetics
- Molecular Biology
Background:
- Primary aldosteronism, characterized by hypertension and excess aldosterone, has two main subtypes: aldosterone-producing adenoma (APA) and idiopathic hyperaldosteronism (IHA).
- IHA typically presents with lower renin suppression, aldosterone levels, and milder hypokalemia compared to APA.
- The aldosterone synthase gene, CYP11B2, plays a crucial role in aldosterone production.
Purpose of the Study:
- To investigate the genetic analysis of the CYP11B2 gene in patients with primary aldosteronism.
- To review recent studies on genetic factors contributing to APA and IHA.
- To explore potential genetic underpinnings for aldosterone overproduction in IHA.
Main Methods:
- Genetic analysis of CYP11B2, CYP11B1, and CYP21 genes in patients with APA and IHA.
- Screening for chimeric CYP11B1/CYP11B2 genes.
- Quantification of CYP11B2 messenger RNA (mRNA) levels in tumor and non-tumor tissues, and leukocytes.
Main Results:
- No mutations were found in the coding regions of CYP11B2, CYP21, or CYP11B1 genes in patients with APA or IHA.
- The chimeric CYP11B1/CYP11B2 gene was not detected in any patient samples.
- Significantly higher CYP11B2 mRNA levels were observed in aldosteronoma tissue compared to nonadenomatous tissue.
- Overexpression of CYP11B2 mRNA was noted in mononuclear leukocytes of IHA patients, suggesting potential promoter region abnormalities or unidentified stimulating factors.
Conclusions:
- Mutations in the coding regions of CYP11B2, CYP21, or CYP11B1 do not appear to be the primary cause of APA or IHA.
- The overexpression of CYP11B2 mRNA in IHA suggests dysregulation of aldosterone synthesis may involve factors beyond direct gene mutations, possibly related to promoter activity or external stimuli.
- Further research into CYP11B2 gene variants and regulatory elements is warranted to understand susceptibility to IHA.
Related Concept Videos
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...